Consolidated Statements of Changes in Stockholders’ Deficit - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2018		4,219,606
Beginning balance at Dec. 31, 2018	$ (107,539)	$ 0	$ 21,833	$ (128,632)	$ (740)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)	1,392	1,392
Stock options exercised, net of $5 receivable	$ 5		5
Stock-based compensation	566		566
Other comprehensive income	(2)				(2)
Net loss	$ (15,283)			(15,283)
Ending balance (in shares) at Dec. 31, 2019	4,220,998	4,220,998
Ending balance at Dec. 31, 2019	$ (122,253)	$ 0	22,404	(143,915)	(742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)		3,346
Stock options exercised, net of $5 receivable	13		13
Stock-based compensation	132		132
Conversion of shares in connection with the Reverse Merger (in shares)		23,933,949
Conversion of preferred shares in connection with the Reverse Merger	85,658	$ 3	85,655
Shares redeemed (in shares)		(52,773)
Shares redeemed in connection with the Reverse Merger	(211)		(211)
Shares issued in connection with the Reverse Merger (in shares)		1,650,000
Shares issued in connection with the Reverse Merger	(50)		(50)
Issuance of common stock, net (in shares)		5,380,000
Issuance of common stock, net of $3.1 million offering cost excluding warrant cost of $223 thousand	19,741	$ 1	19,740
Other comprehensive income	(12)				(12)
Net loss	(4,187)			(4,187)
Ending balance (in shares) at Mar. 31, 2020		35,135,520
Ending balance at Mar. 31, 2020	$ (21,169)	$ 4	127,683	(148,102)	(754)
Beginning balance (in shares) at Dec. 31, 2019	4,220,998	4,220,998
Beginning balance at Dec. 31, 2019	$ (122,253)	$ 0	22,404	(143,915)	(742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)	6,821	6,821
Stock options exercised, net of $5 receivable	$ 27		27
Restricted stocks issued (in shares)	139,501
Stock-based compensation	$ 1,525		1,525
Conversion of shares in connection with the Reverse Merger (in shares)		23,933,949
Conversion of preferred shares in connection with the Reverse Merger	85,658	$ 3	85,655
Shares redeemed (in shares)		(52,773)
Shares redeemed in connection with the Reverse Merger	(211)		(211)
Shares issued in connection with the Reverse Merger (in shares)		1,650,000
Shares issued in connection with the Reverse Merger	(50)		(50)
Issuance of common stock, net (in shares)		10,380,000
Issuance of common stock, net of $3.1 million offering cost excluding warrant cost of $223 thousand	33,387	$ 1	33,386
Other comprehensive income	(30)				(30)
Net loss	$ (17,909)			(17,909)
Ending balance (in shares) at Dec. 31, 2020	40,278,496	40,278,496
Ending balance at Dec. 31, 2020	$ (19,856)	$ 4	142,736	(161,824)	(772)
Beginning balance (in shares) at Feb. 11, 2020	50,325,662
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued in connection with the Reverse Merger (in shares)	1,650,000
Ending balance (in shares) at Feb. 12, 2020	4,171,571
Beginning balance (in shares) at Dec. 31, 2020	40,278,496	40,278,496
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)	500	500
Stock options exercised, net of $5 receivable	$ 2		2
Restricted stocks issued (in shares)	3,000
Stock-based compensation	$ 513		513
Issuance of common stock, net (in shares)		250,000
Issuance of common stock, net of $3.1 million offering cost excluding warrant cost of $223 thousand	950		950
Other comprehensive income	(85)				(85)
Net loss	$ (6,579)			(6,579)
Ending balance (in shares) at Mar. 31, 2021	40,278,496	40,531,996
Ending balance at Mar. 31, 2021	$ (25,055)	$ 4	$ 144,201	$ (168,403)	$ (857)